Phathom Pharmaceuticals Long Term Debt

As of the most recent data (June 2026), PHAT shows a long-term debt of $1.9M. That compares with $550M in the prior-year period — down 99.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHAT's long-term debt is now $1.9M (was $550M) — a 99.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Phathom Pharmaceuticals is outperforming or lagging.

Tracking PHAT's long-term debt over time shows whether Phathom Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $1.9M That compares with $550M in the prior-year period — down 99.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Phathom Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.9M) with ownership activity and broader fundamentals.

Phathom Pharmaceuticals's long-term debt is $1.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.